

CORCEPT THERAPEUTICS INC

Form 8-K

March 22, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

**Date of Report: March 22, 2012**  
**(Date of earliest event reported)**

**Corcept Therapeutics Incorporated**  
**(Exact name of registrant as specified in its charter)**

**DE**

**(State or other jurisdiction  
of incorporation) 000-50679**

**(Commission File Number) 77-0487658**

**(IRS Employer**

**Identification Number)**

**149 Commonwealth Drive, Menlo Park, CA**

**(Address of principal executive offices) 94025**

**(Zip Code)**

**650-327-3270**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events**

In a press release issued on March 22, 2012, we announced that we would be ready to ship Korlym(TM) (mifepristone) 300 mg Tablets to patients by April 11th, three weeks ahead of the our previously announced launch date. We also stated that the wholesale acquisition price would be \$0.62 per milligram and that we would offer financial assistance and other support to patients who are prescribed the medicine.

The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

**(a) Financial statements:**

None

**(b) Pro forma financial information:**

None

**(c) Shell company transactions:**

None

**(d) Exhibits**

99.1 Press Release of Corcept Therapeutics Incorporated dated March 22, 2012

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 22, 2012

**CORCEPT THERAPEUTICS INCORPORATED**

By: /s/ G. Charles Robb

G. Charles Robb

*Chief Financial Officer*

---

**Exhibit Index** **Exhibit No.** **Description** 99.1 Press Release of Corcept Therapeutics Incorporated dated March 22, 2012